Refine by
Biomarker Testing Articles & Analysis
55 news found
Its expertise spans various preclinical services, including efficacy testing, pharmacokinetics, toxicology, and biomarker development, to support clients in their research and development efforts. ...
The use of mouse models enables the study of diabetes in a way that closely mirrors the disease in humans, helping to explore disease mechanisms, find biomarkers, and evaluate potential treatments. Ace Therapeutics provides diverse diabetic mouse models targeting type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM). The T1DM ...
HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays. ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). ...
ByTempus
Alfa Chemistry is able to design and conduct in vivo and in vitro pharmacokinetic (PK) tests for different projects, providing complete pharmacokinetic evaluation and optimization services, including: biological target validation, early physical and chemical properties screening, metabolite identification (metid), in vitro studies, in vivo studies, etc. ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the ...
Such biomarker-based tests will also be essential for precisely monitoring a patient’s response to new ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. ...
-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. ...
BynVector
“We are excited to transfer our knowledge and facilitate the routine use of comprehensive biomarker testing in other laboratories,” stated Jean-Pol Detiffe, Chief Strategy and Innovation Officer and Founder of OncoDNA. “While OncoDEEP has been our flagship biomarker test since 2014, we see more and more ...
The new precision molecular oncology research center will drive the development of targeted next-generation cancer therapies, including efforts to help people living with cancer benefit from molecular tests and targeted treatments through biomarker testing. Bayer has a 160-year track record of delivering scientific innovation for patients in ...
ByBayer AG
From a simple blood draw, the test identifies patients with actionable biomarkers more quickly than starting with tissue biopsy. The VHIO testing services will be available for clinical research and clinical care. “The opening of this service will give more patients with advanced cancer access to blood-based biomarker ...
” Highlights from the first quarter and recent weeks include: The American College of Gastroenterology (“ACG”) updated its clinical guideline for the diagnosis and management of esophageal precancer, endorsing, for the first time, nonendoscopic biomarker screening to detect precancer and prevent highly lethal esophageal cancer, providing support for ...
The updated guideline supports esophageal precancer screening utilizing Lucid’s EsoGuard® DNA Test on samples collected with its EsoCheck® Cell Collection Device, the only such nonendoscopic biomarker screening test available. ...
“Securing broad commercial reimbursement for EsoGuard testing is one of our most important near-term strategic goals and key value drivers. ...
That’s why early detection is crucial; for patients with local to regional prostate cancer (PCa), the 5 year survival rate is nearly 100%, but drops to 30% once the cancer begins to spread to other organs.1 The current standard diagnostic pathway is a PSA test followed by a systematic biopsy if the results are positive. The PSA test is a highly sensitive ...
The development of new diagnostics generates value not only in the diagnostic tests themselves, but also in downstream care pathways. Tests for new biomarkers that use new analytical techniques are developed to enable faster, more sensitive and more specific disease diagnosis, thereby improving patient outcomes and reducing healthcare costs. ...
“We are delighted to transfer our OncoDEEP technology to further enhance Synlab in the field of molecular diagnostics for clinical oncology,” stated Bernard Courtieu, CEO of OncoDNA. “Biomarker testing has the potential to improve patient outcomes and health quality. ...